For citations:
Mamedova A.A., Mochkin N.E., Sarzhevskiy V.O., Demina E.A., Bogatyrev V.S., Spornik A.A., Samoylova A.A., Rukavitsin A.A., Smirnova E.G., Bannikova A.E., Melnichenko V.Ya., Mikhaylova N.B., Borzenkova E.S., Stelmakh L.V., Zalyalov Yu.R., Semenova A.A., Tumyan G.S., Danilova M.A., Konova O.A., Falaleeva N.A., Terekhova A.Yu., Vernyuk M.A., Chervontseva A.M., Khayrullina L.S., Maslov A.A., Lysenko I.B., Alekseeva Yu.A., Pavlyuchenko E.S., Mirsaitov A.A., Zverkova A.A., Ishmatova I.V., Volchenkov S.A., Motalkina M.S., Zyuzgin I.S. Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2nd line treatment before autologous hematopoietic stem cell transplantation (preliminary results). Oncohematology. 2022;17(3):40-47. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-3-40-47
Email this article 